• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

This Market Is Just a Puppet on a String

Stick with energy stocks, and realize that in the current no-yield world stocks are bonds.
By JIM COLLINS
Dec 02, 2021 | 09:00 AM EST
Stocks quotes in this article: IWM, PFE, BNTX, ARCT, ZM, PTON, XOM

When I want to know what is happening with world health and epidemiology, broadly speaking, my first source of info is always...the Russell 2000. Seriously? What the...

The mere mention of a single Omicron case in the USA sent the markets plunging yesterday afternoon. Interactive Brokers sends me alerts when markets move more than 2%. Yesterday I received one in the morning ( (IWM) +2%) and then another one ( (IWM) -2%,) helpfully sent at 4:07 pm ET. The jump in the morning was just as puzzling as the drop in the afternoon, but, man, this market is just a puppet on a string.

As a community, those of us in the investing world are just so addicted to the narrative. It's sad. It has totally replaced equity research, at least in the short term. The narrative entering yesterday's trading session was that the global economy, especially in the U.S was rocking along and would produce above-average corporate earnings growth until kingdom come, Omicron be damned.

That narrative completely ignores the deleterious impact of inflation on corporate profitability. But just as I injured my ankle climbing up into the roof to scream that at the top of my lungs, we have one case of Omicron in the U.S., and, bam, the narrative goes the other way.

Let's just focus on the truth.

  • Stocks are more fully valued than they have ben at any time in this economic cycle. The S&P 500's P/E is higher and its yield lower than at any time since the Crash of 2008.
  • Winter is coming. For the Northern Hemisphere that means more seasonal ailments, and unfortunately one of whose is Covid-19.

As I mentioned in prior RM columns, I had Covid, and trust me when I tell you that you don't want it. I am now fully Pfizered and hoping against hope that mRNA vaccines (like the one developed by Pfizer's (PFE) partner, BioNTech (BNTX) ) last forever. I have done a lot of work on this sector through my research on Arcturus Therapeutics (ARCT) , and I know that such permanence is unlikely. I will get boosted as soon as practicable. Will that booster protect me against Omicron? I don't know, and I don't think anyone does.

It just breaks my heart to go to worldometers.info every day, but it is part of my job. The U.S dropped more than 100,000 new cases and more than 1,600 COVID fatalities yesterday. The human race has done a horrible job of fighting this virus, with the exception of China, where the per capita case numbers are extraordinarily low.

But I try to stick to stocks, not geopolitics. So here goes.

I think broad-based lockdowns are extremely unlikely. They didn't work the first time - again, excluding China - and I just don't see them happening again. Politicians have proven me wrong before. That said, I would be taking profits on Zoom (ZM) here and Peloton (PTON) is still, to quote myself, a disaster, so that's not going to change because of Omicron.

What to buy? Exxon (XOM) almost made me weep yesterday after I downloaded their corporate presentation and searched for "Mozambique." It's right there on page 17. Exxon will continue with its LNG project in Mozambique. As a wannabe Portuguese speaker (I'm still terrible after many trips to Brazil, sadly) and a firm believer that Africa's energy poverty can only be alleviated through hydrocarbon extraction, I was pretty damn happy that XOM is not, as had been rumored, killing its LNG project in Mozambique. Darren Woods and his team appear to have fought off the "wokies" on XOM's Board for now. The world is a better place for that victory. I also own XOM and the market reacted positively to the corporate presentation, so that's a nice bonus.

But that's the inanity of our modern world, especially in Europe. I am in the UK now. It is cold. But politicians want to demonize the very fuels that could keep people warm - and stave off seasonal illnesses, I would hope, during this already cold winter. Meanwhile 5.2 million people have already died of Covid and the arrows are sadly pointing upwards. Ugh.

Stick with energy, be wary of stay-at-home plays and realize that in the current no-yield world (thanks, Janet and Jerome) stocks ARE bonds. Not as an asset class, given the puny S&P 500 yield that I mentioned above, but there are high-yielding dividend-safe outliers in this yield-free market... XOM certainly is one. Own safety.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jim Collins' firm owned XOM and was Short PTON.

TAGS: Investing | Markets | Politics | Rates and Bonds | Stocks | Trading | Energy | Coronavirus

More from Investing

Hot for AI Stocks? Try This Intelligent Approach to Artificial Intelligence

Bob Byrne
Feb 7, 2023 8:30 AM EST

Rather than get burned by issues with suddenly inflated prices that eventually could crash back to earth, go with tried-and true-names in technology development.

Can Pfizer's Charts and Fundamentals Get on the Same Page?

Bruce Kamich
Feb 7, 2023 8:15 AM EST

The pharmaceutical giant gained an analyst's buy recommendation but its technical signals are lackluster at best.

Skyworks Solutions Is Improving but Doesn't Appear to Be Heading Skyward

Bruce Kamich
Feb 7, 2023 7:50 AM EST

The charts indicate that the shares of the semiconductor maker are likely to trade sideways for a while even as it gains an analyst's buy recommendation.

This Stock Deserves More Than Window-Shopping

Paul Price
Feb 7, 2023 7:00 AM EST

Macerich is a blast from the past that still looks good today.

Calm, Collected Change in Sentiment

Helene Meisler
Feb 7, 2023 6:00 AM EST

We're not yet seeing much panic or selling, but did you see that rally in the buck? Let's break it down.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:22 AM EST REAL MONEY

    LIVE EVENT: Bruce Kamich and Todd Campbell Share Their Stock Market Insights

    This Monday, Feb. 6 at 12 p.m., our very own exper...
  • 02:58 PM EST REAL MONEY

    Sarge Guilfoyle Breaks Down the Jobs Report, Fed Policy and Stocks!

    Watch it here!
  • 11:35 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading an Irrational Market
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login